Clinical Trial Update: A Phase 1 Study of GC1102 (Recombinant Hepatitis B Immunoglobulin) in Chronic Hepatitis B Patients [Phase 1]

View source ↗

Summary

Phase 1 study of GC1102, a recombinant hepatitis B immunoglobulin, in chronic hepatitis B patients has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• GC1102 (Hepatitis B immunoglobulin, recombinant)

Snippet

Sponsor: Green Cross Corporation | Conditions: Chronic Hepatitis B | Phase 1 | Status: COMPLETED